莫努匹韦治疗COVID-19患者的2a期临床试验显示加速SARS-CoV-2 RNA清除并消除传染性病毒
这项2a期双盲、安慰剂对照、随机、多中心临床试验在202例未接种疫苗且症状持续时间<7天的确诊SARS-CoV-2感染参与者中评估核苷类似物莫努匹韦的安全性、耐受性和抗病毒疗效。800 mg莫努匹韦组病毒RNA清除时间(中位14天)较安慰剂组(中位15天)缩短(log rank P=0.013),治疗第3天800 mg组1.9%检出传染性病毒而安慰剂组为16.7%(P=0.016)。莫努匹韦在所有剂量下耐受良好。
要点
- 800 mg莫努匹韦组病毒RNA清除中位14天,安慰剂组中位15天,log rank P=0.013。
- 治疗第3天800 mg组1.9%检出传染性病毒,安慰剂组16.7%,P=0.016。
- 治疗第5天400或800 mg组均未分离出传染性病毒,安慰剂组11.1%。
核心结论
- 莫努匹韦800 mg加速SARS-CoV-2 RNA清除并消除传染性病毒,所有剂量耐受良好。
研究设计与样本
- 2a期双盲、安慰剂对照、随机、多中心临床试验,纳入202例未接种疫苗且症状持续时间<7天的确诊SARS-CoV-2感染参与者。
- 参与者按1:1随机接受莫努匹韦200 mg或安慰剂,随后按3:1随机接受莫努匹韦400或800 mg或安慰剂,口服每日两次,共5天。
主要发现
- 病毒RNA清除时间(主要终点)在800 mg莫努匹韦组中位14天,安慰剂组中位15天,log rank P=0.013。
- 研究结束时(4周),800 mg莫努匹韦组92.5%参与者实现病毒RNA清除,安慰剂组为80.3%。
- 治疗第3天,800 mg莫努匹韦组1.9%的鼻咽拭子样本检出传染性病毒,安慰剂组为16.7%(P=0.016)。
- 治疗第5天,400或800 mg莫努匹韦组均未从任何参与者中分离出传染性病毒,安慰剂组为11.1%(P分别为0.034和0.027)。
- 莫努匹韦在所有剂量下耐受良好。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression to severe coronavirus disease 2019 (COVID-19). In a phase 2a double-blind, placebo-controlled, randomized, multicenter clinical trial, we evaluated the safety, tolerability, and antiviral efficacy of the nucleoside analog molnupiravir in 202 unvaccinated participants with confirmed SARS-CoV-2 infection and symptom duration <7 days. Participants were randomized 1:1 to receive molnupiravir (200 mg) or placebo and then 3:1 to receive molnupiravir (400 or 800 mg) or placebo, orally twice daily for 5 days. Antiviral activity was assessed by reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 RNA in nasopharyngeal swabs. Infectious virus was assessed by inoculation of cultured Vero cells with samples from nasopharyngeal swabs and was detected by RT-PCR. Time to viral RNA clearance (primary endpoint) was decreased in the 800-mg molnupiravir group (median 14 days) compared to the placebo group (median 15 days) (log rank P value = 0.013). Of participants receiving 800 mg of molnupiravir, 92.5% achieved viral RNA clearance compared with 80.3% of placebo recipients by study end (4 weeks). Infectious virus (secondary endpoint) was detected in swabs from 1.9% of the 800-mg molnupiravir group compared with 16.7% of the placebo group at day 3 of treatment (P = 0.016). At day 5 of treatment, infectious virus was not isolated from any participants receiving 400 or 800 mg of molnupiravir compared with 11.1% of placebo recipients (P = 0.034 and 0.027, respectively). Molnupiravir was well tolerated across all doses.
引用
- Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022. PMID: 34941423. doi:10.1126/scitranslmed.abl7430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。